Conditions: Hepatocholangiocarcinoma; Fibrolamellar Carcinoma; Hepatic Epithelioid Hemangioendothelioma; Hepatoblastoma; Hepatic Neuroendocrine Carcinoma; Hepatic Carcinosarcomas; Hepatic Cystadenoma; Hepatic Leiomyosarcomas; Hepatic Angiosarcomas; Cholangiocarcinoma
Sponsors: Federation Francophone de Cancerologie Digestive; Société Nationale Française de Gastroentérologie
Recruiting
Feeds
32933 items (32933 unread) in 74 feeds
Acinar Cell Carcinoma
(534 unread)
Acinic Cell Carcinoma
(314 unread)
Adenoid Cystic Carcinoma
(566 unread)
Adrenal Gland Cancer
(2429 unread)
Ampulla Of Vater
(469 unread)
Anal Cancer
(2709 unread)
Angiosarcoma
(990 unread)
Appendix Cancer
(684 unread)
Bile Duct Cancer
(4355 unread)
Brain and CNS
(6120 unread)
Carcinoid
(887 unread)
Endocrine/Neuroendocrine
(5825 unread)
Gall Bladder Cancer
(1132 unread)
Hemangioendothelioma
(1176 unread)
Hepatoblastoma
(770 unread)
Pancreas
(563 unread)
Phyllodes
(384 unread)
PMP and Mucinous Tumors
(477 unread)
Rhabdomyosarcoma
(1118 unread)
Sarcoma
(1431 unread)
Trial - Hemangioendothelioma (16 unread)
-
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Posted: August 7th, 2024, 11:00pm UTC
-
A Phase I Clinical Study of BGC515 Capsules in Patients With Advanced Solid Tumors
Posted: June 11th, 2024, 11:00pm UTC
Conditions: Mesothelioma; Epithelioid Hemangioendothelioma(EHE); Solid Tumor
Interventions: Drug: BGC515
Sponsors: BridGene Biosciences Inc.
Recruiting -
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
Posted: May 10th, 2024, 11:00pm UTC
Conditions: Epithelioid Hemangioendothelioma; Sarcoma,Soft Tissue
Sponsors: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting -
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
Posted: April 28th, 2022, 11:00pm UTC
Conditions: Kaposiform Hemangioendothelioma
Interventions: Other
Sponsors: Children's Hospital of Fudan University
Recruiting -
Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma
Posted: April 12th, 2022, 11:00pm UTC
Conditions: Hemangioendothelioma
Interventions: Drug: Sirolimus
Sponsors: West China Hospital
Recruiting -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Posted: February 8th, 2022, 1:00am UTC
Conditions: Solid Tumors, Adult; Solid Tumor; Malignant Pleural Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions
Interventions: Drug: IK-930; Drug: Osimertinib
Sponsors: Ikena Oncology
Active, not recruiting -
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
Posted: June 10th, 2021, 11:00pm UTC
Conditions: Kaposiform Hemangioendothelioma; Tufted Angioma; Superficial Vascular Anomalies; Superficial Lymphatic Malformations
Interventions: Drug: Percutaneous sirolimus; Drug: Oral sirolimus
Sponsors: Children's Hospital of Fudan University
Recruiting -
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Posted: March 5th, 2021, 1:00am UTC
Conditions: Advanced Sarcoma
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Parker Institute for Cancer Immunotherapy
Active, not recruiting -
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
Posted: March 1st, 2021, 1:00am UTC
Conditions: Kaposiform Hemangioendothelioma
Interventions: Drug: Sirolimus
Sponsors: West China Hospital
Completed -
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Posted: August 14th, 2019, 11:00pm UTC
Conditions: Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma
Interventions: Drug: Tacrolimus ointment
Sponsors: West China Hospital
Recruiting -
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Posted: May 30th, 2019, 11:00pm UTC
Conditions: Soft Tissue Sarcoma; Clear Cell Sarcoma; Epithelioid Sarcoma; Perivascular Epithelioid Cell Neoplasms; Desmoplastic Small Round Cell Tumor; Malignant Solitary Fibrous Tumors; Alveolar Soft Part Sarcoma; Epithelioid Hemangioendothelioma; Low Grade Fibromyxoid Sarcoma; Sclerosing Epithelioid Fibrosarcoma
Interventions: Other: Patient with Soft Tissue Sarcoma
Sponsors: Institut Claudius Regaud
Recruiting -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Posted: November 14th, 2018, 1:00am UTC
Conditions: Malignant Solid Tumors; Other Neoplasms Solid Tumors; Pediatric Solid Tumor; Refractory Solid Tumors; Solid Tumor
Sponsors: National Cancer Institute (NCI)
Recruiting -
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Posted: January 29th, 2018, 1:00am UTC
Conditions: Sarcoma
Interventions: Drug: Epacadostat; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Incyte Corporation; Merck Sharp & Dohme LLC; M.D. Anderson Cancer Center
Active, not recruiting -
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Posted: September 11th, 2017, 11:00pm UTC
Conditions: Soft Tissue Sarcoma; Bone Sarcoma
Interventions: Drug: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]; Drug: Nivolumab 100 MG/10 ML [Opdivo]; Drug: Epirubicin; Drug: Ifosfamide; Drug: Doxorubicin; Drug: Dacarbazine; Drug: Cisplatin; Drug: Methotrexate
Sponsors: Grupo Espanol de Investigacion en Sarcomas
Completed -
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Posted: June 28th, 2016, 11:00pm UTC
Conditions: Advanced and/or Metastatic Sarcoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: M.D. Anderson Cancer Center; MedImmune LLC
Completed -
Lymphatic Anomalies Registry for the Assessment of Outcome Data
Posted: March 26th, 2015, 11:00pm UTC
Conditions: Lymphatic Malformation; Generalized Lymphatic Anomaly (GLA); Central Conducting Lymphatic Anomaly; CLOVES Syndrome; Gorham-Stout Disease ("Disappearing Bone Disease"); Blue Rubber Bleb Nevus Syndrome; Kaposiform Lymphangiomatosis; Kaposiform Hemangioendothelioma/Tufted Angioma; Klippel-Trenaunay Syndrome; Lymphangiomatosis
Sponsors: Boston Children's Hospital; Lymphatic Malformation Institute
Recruiting